These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18269343)

  • 21. Targeted cancer therapeutics.
    Hait WN; Hambley TW
    Cancer Res; 2009 Feb; 69(4):1263-7; discussion 1267. PubMed ID: 19208830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic targeting of CD70 and CD27.
    Wajant H
    Expert Opin Ther Targets; 2016 Aug; 20(8):959-73. PubMed ID: 26914723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-based therapeutics: focus on prostate cancer.
    Ross JS; Gray KE; Webb IJ; Gray GS; Rolfe M; Schenkein DP; Nanus DM; Millowsky MI; Bander NH
    Cancer Metastasis Rev; 2005 Dec; 24(4):521-37. PubMed ID: 16408160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD70: An emerging target in cancer immunotherapy.
    Jacobs J; Deschoolmeester V; Zwaenepoel K; Rolfo C; Silence K; Rottey S; Lardon F; Smits E; Pauwels P
    Pharmacol Ther; 2015 Nov; 155():1-10. PubMed ID: 26213107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.
    Ronca R; Sozzani S; Presta M; Alessi P
    Immunobiology; 2009; 214(9-10):800-10. PubMed ID: 19625102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
    Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
    Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
    Rouleau C; Curiel M; Weber W; Smale R; Kurtzberg L; Mascarello J; Berger C; Wallar G; Bagley R; Honma N; Hasegawa K; Ishida I; Kataoka S; Thurberg BL; Mehraein K; Horten B; Miller G; Teicher BA
    Clin Cancer Res; 2008 Nov; 14(22):7223-36. PubMed ID: 19010839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis.
    Oflazoglu E; Boursalian TE; Zeng W; Edwards AC; Duniho S; McEarchern JA; Law CL; Gerber HP; Grewal IS
    J Immunol; 2009 Sep; 183(6):3770-7. PubMed ID: 19710474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta2-microglobulin: emerging as a promising cancer therapeutic target.
    Shi C; Zhu Y; Su Y; Chung LW; Cheng T
    Drug Discov Today; 2009 Jan; 14(1-2):25-30. PubMed ID: 19056512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel radiolabeled antibody conjugates.
    Goldenberg DM; Sharkey RM
    Oncogene; 2007 May; 26(25):3734-44. PubMed ID: 17530026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV.
    Ho DT; Wykoff-Clary S; Gross CS; Schneider D; Jin F; Kretschmer PJ; Hermiston TW
    Cancer Gene Ther; 2009 Feb; 16(2):184-94. PubMed ID: 18758433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of vascular endothelium-specific drug-targeting strategies for the treatment of cancer.
    Molema G
    Acta Biochim Pol; 2005; 52(2):301-10. PubMed ID: 15990916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
    Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.
    Burke PJ; Toki BE; Meyer DW; Miyamoto JB; Kissler KM; Anderson M; Senter PD; Jeffrey SC
    Bioorg Med Chem Lett; 2009 May; 19(10):2650-3. PubMed ID: 19386499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.
    Sahin U; Koslowski M; Dhaene K; Usener D; Brandenburg G; Seitz G; Huber C; Türeci O
    Clin Cancer Res; 2008 Dec; 14(23):7624-34. PubMed ID: 19047087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
    Huq A; Singh B; Meeker T; Mascarenhas D
    Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors.
    Baloglu E; Miller ML; Roller EE; Cavanagh EE; Leece BA; Goldmacher VS; Chari RV
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5885-8. PubMed ID: 15501062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted drug delivery strategies to treat lung metastasis.
    Bar J; Herbst RS; Onn A
    Expert Opin Drug Deliv; 2009 Oct; 6(10):1003-16. PubMed ID: 19663628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.